Evidence map›Paper›PMID 42151723›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Metabotropic glutamate receptor 5 is associated with plasma GFAP dependent on age.

Tangyue Hu, Yan Wang, Jie Wang, Xiaoxie Mao, Shuhua Ren, Kun He, Yihui Guan, Qi Huang, Binyin Li, Fang Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tangyue HuDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Yan WangDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Jie WangDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Xiaoxie MaoDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Shuhua RenDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Kun HeDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Yihui GuanDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Qi HuangDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Binyin LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fang XieDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-2667-281X

Funding

China Postdoctoral Science Foundation GZC20251473Clinical Research Plan of SHDC SHDC2020CR2056BLingang Laboratory LGL-3142-ADB510100National Science Foundation of China 81801752National Science Foundation of China 82071962National Science Foundation of China 82171473National Science Foundation of China 82201583Shanghai Municipal Key Clinical Specialty 3030247006STI2030-Major Projects 2022ZD0213800The Shanghai Municipal Science and Technology Major Project 2018SHZDZX01The Shanghai Sailing Program 19YF1405300The startup fund of Huashan Hospital, Fudan University 2017QD081
6 · The paper itself

Abstract

introductionWe investigated the relationship between metabotropic glutamate receptor subtype 5 (mGluR5) availability and plasma biomarkers in individuals with cognitive impairment.

methodsSeventy-one subjects were included (17 cognitively unimpaired [CU], 10 early-onset cognitive impairment [EOCI], and 44 late-onset cognitive impairment [LOCI]). Amyloid beta (Aβ) pathology was quantified using

resultsIn individuals aged over 65 years and the LOCI group, mGluR5 availability was positively associated with plasma glial fibrillar acidic protein (GFAP). This positive relationship of mGluR5 with plasma GFAP in LOCI only survived in the Aβ-positive subgroup (r = 0.475, p = 0.011). DISCUSSION: Increased mGluR5 availability is significantly associated with elevated plasma GFAP levels dependent on age in individuals aged over 65 years and the LOCI group.

Indexed as

AgingCognitive DysfunctionGlial Fibrillary Acidic ProteinReceptor, Metabotropic Glutamate 5AgedAged, 80 and overAge FactorsAmyloid beta-PeptidesBiomarkersFemaleHumansMaleAmyloid beta-PeptidesBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinGRM5 protein, humanReceptor, Metabotropic Glutamate 5agingcognitive impairmentGFAPmetabotropic glutamate receptor subtype 5 (mGluR5)plasma biomarkers

Identifiers

PMID42151723
PMCPMC13183592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.